US FDA approves Boehringer Ingelheim’s lung cancer treatment Reuters Top German Pharma Boehringer Wins US Approval for Cancer Drug Bloomberg.com FDA Grants Accelerated Approval to Zongertinib for Nonsquamous NSCLC With HER2 TKD Mutations OncLive Amol Akhade: Zongertinib – A New Targeted Therapy Option for a Rare Molecular Subset of Lung Cancer Oncodaily Boehringer Ingelheim breaks into oncology with FDA approval for lung cancer med …
Read More »